COMMUNIQUÉS West-GlobeNewswire

Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
21/04/2026
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset entering a Phase I [...]
RAMSAY SANTE : mise à disposition du rapport financier semestriel au 31 décembre 2025
21/04/2026
Paris, le 21 avril 2026 RAMSAY SANTE Mise à disposition du rapport financier semestriel au 31 décembre 2025 Ce document est disponible sur le site internet de RAMSAY SANTE : http://www.ramsaysante.fr À propos de Ramsay [...]
Sotera Health Announces First-Quarter 2026 Earnings Release Date
21/04/2026
CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare [...]
Hyalex Orthopaedics Announces FDA 510(k) Clearance of the HYALEX Slalom™ MTP Hemiarthroplasty System
21/04/2026
Regulatory milestone positions company for initial commercial entry into large and underserved foot & ankle market LEXINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Hyalex Orthopaedics today announced that it has [...]
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
21/04/2026
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” [...]
XORTX Meets Nasdaq Continued Listing Requirements
21/04/2026
CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026
21/04/2026
Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026 Scarcity of truly tumour- [...]
BPGbio Appoints Former Oxford Pro-Vice Chancellor for Innovation Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer
21/04/2026
• Former Oxford Pro-Vice-Chancellor for Innovation and former Head of Biology at GSK to lead company’s R&D • Longstanding Scientific Advisory Board Chair steps into an expanded leadership role to accelerate the [...]
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
21/04/2026
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 [...]
Annual General and Special Meeting of Shareholders to be held May 7, 2026
21/04/2026
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and [...]
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/04/2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous [...]
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
21/04/2026
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor [...]
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
21/04/2026
BOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. [...]
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
21/04/2026
BEIJING, April 21, 2026 (GLOBE NEWSWIRE) -- At the 2026 American Association for Cancer Research (AACR) Annual Meeting, InnoCare Pharma (HKEX: 9969; SSE: 688428) presented preclinical data of its novel B7-H3 targeted [...]
Dark Horse Consulting Group’s Acquisition of CJ PARTNERS Provides Regional Expansion
21/04/2026
WALNUT CREEK, Calif. and TOKYO, April 21, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”) today announced the acquisition of CJ PARTNERS (“CJP”), a distinguished consulting and advisory firm [...]
Groundbreaking approaches such as cell therapies on the horizon for transformation of neural hearing loss, Rinri Therapeutics’ review1 shows
21/04/2026
Elevating the importance of neural health via better diagnosis and treatment is crucial for restoration of natural hearing, JARO review concludes Sheffield, UK, April 21, 2026 (GLOBE NEWSWIRE) -- The role of neural [...]
Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit™, as it moves to commercialization
21/04/2026
CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercialization aXess™ reduces the need for vascular access interventions enabling more [...]
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
21/04/2026
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset entering a Phase I [...]
Transactions in connection with share buy-back program
21/04/2026
Company announcement no. 11 - 26 21 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]

Pages